{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:56:13Z","timestamp":1753890973496,"version":"3.41.2"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Gastroenterol."],"abstract":"<jats:p>Acute Severe Ulcerative Colitis (ASUC) is a well-known and potentially fatal disease state, characterized by symptoms of systemic toxicity including fever, severe anemia, elevated inflammatory markers, and autonomic instability. The life-threatening nature of this condition requires clinicians to make prompt diagnoses and take rapid action, either directing patients towards surgical interventions or medical management. Failure to treat ASUC may lead to toxic dilation of the colon, hemorrhage, or sepsis. Current algorithms suggest the use of intravenous (IV) corticosteroids upon diagnosis, with transition to oral corticosteroids, calcineurin inhibitors or tumor necrosis factor (TNF) inhibitors upon reduction of severe symptoms for candidates deemed to be amenable to medical management. Within these classes, TNF inhibitors such as Infliximab (IFX) have proven to be the most safe, efficacious, and tolerable for patients. While IFX has much data supporting its benefits in achieving short term remission, there are still high rates of long-term need for colectomy and failure to maintain remission. This is due to interactions between the inflamed gastrointestinal tract, the increased metabolic activity seen in ASUC, and intrinsic pharmacodynamic properties of IFX. Certain novel studies suggest that Janus Kinase (JAK-STAT) inhibitors such as Tofacitinib and Upadacitinib are potent agents to salvage clinical remission achieved by IFX, upon its failure. Here we discuss methods to optimize the dosing of IFX to maximize its efficacy, while exploring recent work done on the safety and efficacy of JAK-STAT inhibitors as a salvage therapy, therefore suggesting a novel treatment algorithm to improve clinical outcomes in medically managed ASUC patients.<\/jats:p>","DOI":"10.3389\/fgstr.2024.1488288","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T06:24:12Z","timestamp":1732515852000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute severe ulcerative colitis: using JAK-STAT inhibitors for improved clinical outcomes"],"prefix":"10.3389","volume":"3","author":[{"given":"Shruthi","family":"Karthikeyan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chetan","family":"Ambastha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kian","family":"Keyashian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"B1","unstructured":"Acute severe ulcerative colitis: Symptoms, causes, and more"},{"key":"B2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5009\/GNL220017","article-title":"Acute severe ulcerative colitis: optimal strategies for drug therapy","volume":"17","author":"Nakase","year":"2023","journal-title":"Gut Liver"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/J.CROHNS.2010.02.001","article-title":"The pattern and outcome of acute severe colitis","volume":"4","author":"Dinesen","year":"2010","journal-title":"J Crohns Colitis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/MOG.0000000000000739","article-title":"Diagnosis and management of clostridioides difficile infection in patients with inflammatory bowel disease","volume":"37","author":"Dalal","year":"2021","journal-title":"Curr Opin Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/gut.27.10.1210","article-title":"Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis","volume":"27","author":"Chapman","year":"1986","journal-title":"Gut"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/003655201750305503","article-title":"A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis","volume":"36","author":"Mantzaris","year":"2001","journal-title":"Scand J Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/GUT.26.12.1380","article-title":"Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis","volume":"26","author":"Dickinson","year":"1985","journal-title":"Gut"},{"key":"B9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/IBD\/IZY208","article-title":"Contemporary medical management of acute severe ulcerative colitis","volume":"25","author":"Whaley","year":"2019","journal-title":"Inflammation Bowel Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/IMJ.12488","article-title":"Venous thromboembolism and underutilisation of anticoagulant thromboprophylaxis in hospitalised patients with inflammatory bowel disease","volume":"44","author":"Dwyer","year":"2014","journal-title":"Intern Med J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/J.CROHNS.2013.03.002","article-title":"Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients","volume":"7","author":"Ra","year":"2013","journal-title":"J Crohns Colitis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231215148","article-title":"Prevalence and risk factors for early medical and surgical complications following an admission for acute severe ulcerative colitis","volume":"16","author":"Li","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/GUTJNL-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/GUT.38.6.905","article-title":"Predicting outcome in severe ulcerative colitis","volume":"38","author":"Travis","year":"1996","journal-title":"Gut"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/J.1365-2036.2004.01945.X","article-title":"Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery","volume":"19","author":"Ho","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199810000-00003","article-title":"Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis","volume":"10","author":"Lindgren","year":"1998","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.00607.x","article-title":"Correlation between endoscopic severity and the clinical activity index in ulcerative colitis","volume":"93","author":"Seo","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/ECCO-JCC\/JJX084","article-title":"Faecal calprotectin and UCEIS predict short-term outcomes in acute severe colitis: prospective cohort study","volume":"11","author":"Jain","year":"2017","journal-title":"J Crohns Colitis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4103\/SJG.SJG_145_21","article-title":"The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: A meta-analysis","volume":"27","author":"Zhao","year":"2021","journal-title":"Saudi J Gastroenterol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/APT.13175","article-title":"Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis","volume":"41","author":"Rosen","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/GUTJNL-2014-308099","article-title":"The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study","volume":"65","author":"Yarur","year":"2016","journal-title":"Gut"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/J.CYTO.2009.02.001","article-title":"TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis","volume":"46","author":"Olsen","year":"2009","journal-title":"Cytokine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/J.1572-0241.1999.01149.X","article-title":"Intravenous cyclosporin in ulcerative colitis: a five-year experience","volume":"94","author":"Cohen","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/J.CGH.2006.04.001","article-title":"Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis","volume":"4","author":"Moskovitz","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/GUT.2005.081794","article-title":"A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis","volume":"55","author":"Ogata","year":"2006","journal-title":"Gut"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3748\/WJG.V25.I13.1603","article-title":"Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis","volume":"25","author":"Hoffmann","year":"2019","journal-title":"World J Gastroenterol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000350","article-title":"Systematic review: sequential rescue therapy in severe ulcerative colitis: do the benefits outweigh the risks","volume":"21","author":"Narula","year":"2015","journal-title":"Inflammation Bowel Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/ECCO-JCC\/JJAD036","article-title":"Tofacitinib for acute severe ulcerative colitis: A systematic review","volume":"17","author":"Steenholdt","year":"2023","journal-title":"J Crohn\u2019s Colitis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/J.CGH.2018.07.009","article-title":"Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis","volume":"17","author":"Hanauer","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/ECCO-JCC\/JJAD212.0086","article-title":"DOP46 Tofacitinib for hospitalized acute severe Ulcerative Colitis \u2013 the TRIUMPH study","volume":"18","author":"Narula","year":"2024","journal-title":"J Crohn\u2019s Colitis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/IBD\/IZAB181","article-title":"Success of cyclosporin and tofacitinib combination therapy in a patient with severe steroid-refractory ulcerative colitis","volume":"27","author":"Yang","year":"2021","journal-title":"Inflammation Bowel Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/ECCO-JCC\/JJAD153","article-title":"Tofacitinib versus oral prednisolone for induction of remission in moderately active ulcerative colitis [ORCHID]: A prospective, open-label, randomized, pilot study","volume":"18","author":"Singh","year":"2024","journal-title":"J Crohns Colitis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"463","DOI":"10.5152\/TJG.2022.21093","article-title":"Cyclosporine therapy as a rescue treatment in steroid refractory acute severe ulcerative colitis: A real life data from a tertiary center","volume":"33","author":"Evirgen","year":"2022","journal-title":"Turkish J Gastroenterol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/J.1365-2036.2008.03764.X","article-title":"Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis","volume":"28","author":"Yamamoto","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/ECCO-JCC\/JJV221","article-title":"Efficacy and safety of tacrolimus therapy for active ulcerative colitis; A systematic review and meta-analysis","volume":"10","author":"Komaki","year":"2016","journal-title":"J Crohns Colitis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200105000-00001","article-title":"Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study","volume":"7","author":"Sands","year":"2001","journal-title":"Inflammation Bowel Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1053\/J.GASTRO.2005.03.003","article-title":"Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study","volume":"128","author":"J\u00e4rnerot","year":"2005","journal-title":"Gastroenterology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/S00384-012-1602-8","article-title":"Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis","volume":"28","author":"Chang","year":"2013","journal-title":"Int J Colorectal Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/AJG.2016.7","article-title":"Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids","volume":"111","author":"Narula","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011440","article-title":"Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis","volume":"97","author":"Liu","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/APT.13175","article-title":"Applying pharmacokinetics to optimize dosing of anti-TNF biologics in acute severe ulcerative colitis","volume":"41","author":"Rosen","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/CLPT.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms","volume":"91","author":"Ord\u00e1s","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"B45","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/J.CGH.2015.10.029","article-title":"Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis","volume":"14","author":"Brandse","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/J.GASTRO.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/MPG.0B013E3182A98DF2","article-title":"Outcome following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant inflammatory bowel disease","volume":"58","author":"Falaiye","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B48","unstructured":"Study Details | TITRATE (inducTIon for acuTe ulceRATivE Colitis)\n          \n          ClinicalTrials.gov"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000212","article-title":"Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study","volume":"20","author":"Dotan","year":"2014","journal-title":"Inflammation Bowel Dis"},{"key":"B50","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1208\/S12248-014-9632-5","article-title":"Dashboard systems: implementing pharmacometrics from bench to bedside","volume":"16","author":"Mould","year":"2014","journal-title":"AAPS J"},{"key":"B51","unstructured":"Dosing & Administration | HCP | Infliximab"},{"key":"B52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1136\/GUT.2009.183095","article-title":"Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis","volume":"59","author":"Seow","year":"2010","journal-title":"Gut"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1053\/J.GASTRO.2014.08.035","article-title":"Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis","volume":"147","author":"Adedokun","year":"2014","journal-title":"Gastroenterology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/J.CGH.2018.06.031","article-title":"Effect of accelerated infliximab induction on short- and long-term outcomes of acute severe ulcerative colitis: A retrospective multicenter study and meta-analysis","volume":"17","author":"Nalagatla","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"i1611","DOI":"10.1093\/ECCO-JCC\/JJAD212.1002","article-title":"P872 PREDICT UC: optimising infliximab induction therapy for acute severe ulcerative colitis \u2013 A randomised controlled trial","volume":"18","author":"Choy","year":"2024","journal-title":"J Crohn\u2019s Colitis"},{"key":"B56","unstructured":"No Study Results Posted | Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis\n          \n          ClinicalTrials.gov"},{"key":"B57","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/J.CGH.2014.09.045","article-title":"Pushing the pedal to the metal: should we accelerate infliximabTherapy for patients with severe ulcerative colitis","volume":"13","author":"Herfarth","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/NRGASTRO.2016.116","article-title":"Acute severe ulcerative colitis: From pathophysiology to clinical management","volume":"13","author":"Hindryckx","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/ECCO-JCC\/JJZ032","article-title":"Ciclosporin therapy after infliximab failure in hospitalized patients with acute severe colitis is effective and safe","volume":"13","author":"Weisshof","year":"2019","journal-title":"J Crohns Colitis"},{"key":"B60","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/J.BPG.2018.05.007","article-title":"Acute severe ulcerative colitis: State of the art treatment","author":"Gisbert","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/ECCO-JCC\/JJAD004","article-title":"Rescue therapies for steroid-refractory acute severe ulcerative colitis: A review","volume":"17","author":"Gisbert","year":"2023","journal-title":"J Crohn\u2019s Colitis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/J.DLD.2008.03.014","article-title":"Colectomy rate in acute severe ulcerative colitis in the infliximab era","volume":"40","author":"Aratari","year":"2008","journal-title":"Dig Liver Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2023.05.021","article-title":"The current role of Tofacitinib in acute severe ulcerative colitis in adult patients: A systematic review","volume":"55","author":"Mpakogiannis","year":"2023","journal-title":"Dig Liver Dis"},{"key":"B64","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/039463200401700102","article-title":"Novel shift of Jak\/Stat signalling characterizes the protective effect of aurintricarboxylic acid (ATA) from tumor necrosis factor-\u03b1 toxicity in human B lymphocytes","volume":"17","author":"Marchisio","year":"2004","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/UEG2.12442","article-title":"Review article: Updated management of acute severe ulcerative colitis: From steroids to novel medical strategies","volume":"11","author":"Calm\u00e9jane","year":"2023","journal-title":"United Eur Gastroenterol J"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.7187","article-title":"JAK inhibitor safety compared to traditional systemic immunosuppressive therapies","volume":"21","author":"Daniele","year":"2022","journal-title":"J Drugs Dermatol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1097\/MEG.0000000000002650","article-title":"JAK inhibitors for the treatment of inflammatory bowel disease: results of an international survey of perceptions, attitudes, and clinical practice","volume":"35","author":"Honap","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1016\/j.cgh.2023.03.040","article-title":"Comparative effectiveness of upadacitinib and tofacitinib in inducing remission in ulcerative colitis: real-world data","volume":"21","author":"Boneschansker","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1053\/J.GASTRO.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn\u2019s disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1606910\/SUPPL_FILE\/NEJMOA1606910_DISCLOSURES.PDF","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Balzola","year":"2012","journal-title":"N Engl J Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/ECCO-JCC\/JJAB109","article-title":"Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis","volume":"16","author":"Gilmore","year":"2022","journal-title":"J Crohn\u2019s Colitis"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/IMJ.16192","article-title":"Outcomes out to 12 months after sequential use of high-dose tofacitinib following infliximab in acute severe ulcerative colitis","volume":"53","author":"Eqbal","year":"2023","journal-title":"Intern Med J"},{"key":"B75","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/J.CGH.2018.11.022","article-title":"Efficacy of induction therapy with high-intensity tofacitinib in 4 patients with acute severe ulcerative colitis","volume":"17","author":"Berinstein","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.14309\/AJG.0000000000002674","article-title":"Effectiveness of upadacitinib for patients with acute severe ulcerative colitis: A multicenter experience","author":"Berinstein","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1093\/ECCO-JCC\/JJAD115","article-title":"Upadacitinib salvage therapy for infliximab-experienced patients with acute severe ulcerative colitis","volume":"17","author":"Gilmore","year":"2023","journal-title":"J Crohns Colitis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1093\/IBD\/IZAD180","article-title":"Upadacitinib for acute severe ulcerative colitis","volume":"29","author":"Zinger","year":"2023","journal-title":"Inflammation Bowel Dis"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1093\/IBD\/IZAE191","article-title":"Upadacitinib for acute severe ulcerative colitis: A systematic review","author":"Damianos","year":"2024","journal-title":"Inflammation Bowel Dis"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.940966","article-title":"Upadacitinib as a rescue therapy in acute severe ulcerative colitis: A case report and review of the literature","volume":"24","author":"Ali","year":"2023","journal-title":"Am J Case Rep"}],"container-title":["Frontiers in Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2024.1488288\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T06:24:17Z","timestamp":1732515857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2024.1488288\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":80,"alternative-id":["10.3389\/fgstr.2024.1488288"],"URL":"https:\/\/doi.org\/10.3389\/fgstr.2024.1488288","relation":{},"ISSN":["2813-1169"],"issn-type":[{"type":"electronic","value":"2813-1169"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"article-number":"1488288"}}